Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04756180
Other study ID # PUFA3001
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 2016
Est. completion date April 2019

Study information

Verified date March 2021
Source Abbott
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective was to investigate the effect of 12-week treatment of Omacor on fasting serum triglycerides (TG) in Chinese subjects with hypertriglyceridemia (HTG). The secondary objectives were to investigate the safety and tolerability and effect of Omacor on lipid parameters after 12 weeks treatment.


Description:

This was a multicenter, randomized, double-blind, parallel-group study of twice daily treatment of Omacor or matching placebo in subjects with moderate or severe HTG.


Recruitment information / eligibility

Status Completed
Enrollment 248
Est. completion date April 2019
Est. primary completion date April 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Baseline fasting serum TG level > 200mg/dL and <1000mg/dL, in subjects treated for HTG. - If on previous statin therapy, the treatment should have been kept stable in the last 3 months before entering the study. - Able and willing to give written informed consent. Exclusion Criteria: - Subjects taking fish oil capsules 8 weeks prior to inclusion in this study. - Known allergy to the active ingredient, or fish, soya, corn or olive oild (placebos). - Pregnant of lactating females. - Known increased risk of hemorrhage such as recent surgery, gastrointestinal hemorrhagic disease. - Significant hepatic disease. - Significantly reduced renal function. - Alcohol consumption >30g for male and 20g for female daily. - Concomitant use of other investigational drugs. - Subject related to the investigator. - Subject expected to be not compliant.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Omega-3-acid ethyl ester or Placebo
Omega-3-acid ethyl ester 2 gm/day for first 4 week followed by 4gm/day for 8 week

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Abbott

Outcome

Type Measure Description Time frame Safety issue
Primary Percent change in fasting serum TG Percent change from baseline in fasting serum TG Baseline to end of treatment at treatment week 12
Secondary Change in total cholesterol, LDL-cholesterol, HDL cholesterol, non-HDL-cholesterol and the LDL/HDL ratio Change from baseline in total cholesterol, LDL-cholesterol, HDL cholesterol, non-HDL-cholesterol and the LDL/HDL ratio Between baseline and end of treatment week 12
See also
  Status Clinical Trial Phase
Completed NCT03929198 - Translation of Pritikin Program to the Community N/A
Completed NCT02250105 - Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia Phase 2
Completed NCT02859129 - Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®) Phase 1
Completed NCT01455844 - TRIal For Efficacy of Capre on hyperTriglyceridemiA Phase 2
Completed NCT01437930 - Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients N/A
Completed NCT01010399 - Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects Phase 4
Completed NCT00959842 - Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia Phase 1/Phase 2
Completed NCT00519714 - A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA) Phase 2/Phase 3
Recruiting NCT00186537 - Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides. N/A
Completed NCT00246402 - Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV N/A
Completed NCT06020950 - Chia Seeds Consumption in Hypertriglyceridemia N/A
Completed NCT02354976 - A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects. Phase 2
Completed NCT04966494 - Impact of Beans and Oats Snack Bar on Hypertriglyceridemic Women N/A
Completed NCT04630366 - A Phase 1, First Time in Humans Study of NST-1024 Phase 1
Completed NCT04650152 - Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)
Completed NCT03693131 - Efficacy of MND-2119 in Participants With Hypertriglyceridemia Phase 3
Completed NCT02868177 - Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes Phase 2/Phase 3
Completed NCT01968720 - Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia Phase 2
Completed NCT01462877 - A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic Phase 4
Completed NCT01211847 - Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia Phase 2